Navigation Links
PharmAthene Reports Third Quarter 2011 Financial and Operating Results
Date:11/9/2011

rsuant to an opinion issued September 22, 2011 from the Delaware Court of Chancery, PharmAthene is entitled to 50% of the net profits over 10 years from all sales of SIGA Technologies' ST-246, a novel smallpox antiviral agent being developed by SIGA for the treatment and prevention of morbidity and mortality associated with exposure to the causative agent of smallpox, and related products, once SIGA receives the first $40 million in net profits from sales of ST-246.  For more information about PharmAthene, please visit www.PharmAthene.com.

Statement on Cautionary Factors Except for the historical information presented herein, matters discussed may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "potential"; "believe"; "anticipate"; "intend"; "plan"; "expect"; "estimate"; "could"; "may"; "should"; "will"; "project"; "potential"; or similar statements are forward-looking statements. PharmAthene disclaims any intent or obligation to update these forward-looking statements other than as required by law. Risks and uncertainties include risk associated with the reliability of the results of the studies relating to human safety and possible adverse effects resulting from the administration of the Company's product candidates, unexpected funding delays and/or reductions or elimination of U.S. government funding for one or more of the Company's development programs, the award of government contracts to our competitors, unforeseen safety issues, challenges related to the development, scale-up, technology transfer, and/or process validation of manu
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. PharmAthene Progresses Second Generation rPA Anthrax Vaccine
2. PharmAthene Appoints Brian A. Markison to the Companys Board of Directors
3. PharmAthene Achieves Significant Progress in SparVax™ Anthrax Vaccine Program
4. Department of Defense Awards $5.7 Million Contract to PharmAthene for Nerve Agent Medical Countermeasure Program
5. PharmAthene Selected for Inclusion in the Russell Global Index and Russell 3000 Index
6. PharmAthene Achieves Anthrax Vaccine Program Milestone and Successfully Completes Technology Transfer
7. PharmAthene Completes $6.5 Million Registered Direct Offering
8. PharmAthene Reports First Quarter 2011 Financial and Operating Results
9. PharmAthene to Host Year-End 2010 Earnings Conference Call and Webcast on Monday, March 28, 2011
10. PharmAthene Strengthens Scientific Leadership and Program Management for Future Growth
11. PharmAthene Receives FDA Clearance to Reinitiate Clinical Testing of Valortim®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... prefer to settle into equilibriuma state of unchanging ... realm of non-equilibrium conditions where new possibilities lie. ... phases, such as temperature fluctuations, freezing and melting, ... their body temperature, airplanes to fly, and the ... But even though these conditions exist naturally and ...
(Date:7/24/2014)... N.J. , July 24, 2014  CorMedix ... on developing and commercializing therapeutic products for the ... today announces receipt of notice on July 18, ... the NYSE-MKT has accepted the CorMedix plan to ... NYSE-MKT. As a result, the NYSE-MKT is continuing ...
(Date:7/24/2014)... 2014 1000 balances – 4 steps ... customers’ weighing needs and expertly narrows down the mass ... scales or even terminals. , First, select the ... (or select readability instead) and define the accuracy – ... criteria narrows down the list to models that fit ...
(Date:7/24/2014)... Brook, NJ (PRWEB) July 24, 2014 ... to manage numerous projects in the MENA region during ... to have a preferred provider agreement with DZS to ... the MENA region,” said Global VP of R&D and ... "DZS has developed excellent operational practices with a focus ...
Breaking Biology Technology:New approach to form non-equilibrium structures 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 3SBI Pharmaceuticals Co. Ltd. Enters into Preferred Provider Agreement with DZS Clinical Services 2
... Inc. (Nasdaq: MYL ) today announced ... Biocon Limited, a publicly traded company on the ... the development, manufacturing, supply and commercialization of multiple, ... marketplace. Through this partnership, Mylan and Biocon bring ...
... June 29 , - Financing ... Gyros AB, the leading provider of ... SEK 80 million,(approximately euro 7.5 million) in an equity fundraising ... will enable Gyros to drive,the further commercialization of its Gyrolab ...
... , MENLO PARK, Calif., June 29 Kornberg Associates | ... Stanford University to design a new Cognitive & ... the announcement. The firm has worked with Stanford ... the past 30 years, one of which is the two-story, ...
Cached Biology Technology:Mylan Announces Strategic Collaboration with Biocon to Enter the Global Generic Biologics Market 2Mylan Announces Strategic Collaboration with Biocon to Enter the Global Generic Biologics Market 3Mylan Announces Strategic Collaboration with Biocon to Enter the Global Generic Biologics Market 4Gyros Raises SEK 80 Million to Accelerate the Commercialization of its Gyrolab(R) Systems for the Cost-Efficient Development of Biopharmaceuticals 2Gyros Raises SEK 80 Million to Accelerate the Commercialization of its Gyrolab(R) Systems for the Cost-Efficient Development of Biopharmaceuticals 3Gyros Raises SEK 80 Million to Accelerate the Commercialization of its Gyrolab(R) Systems for the Cost-Efficient Development of Biopharmaceuticals 4Kornberg Associates Architects Selected to Develop Design for New Stanford University Imaging Center 2
(Date:7/24/2014)... , July 24, 2014 /PRNewswire-iReach/ -- The Geneva Healthcare ... cardiac devices, has cut emergency room wait times by ... Diego (UCSD) Medical Center, according to a recent study ... Emergency Departments are using the suite to access data ... or defibrillators. "Using Geneva,s technology platform we ...
(Date:7/24/2014)... average over a 35 year period in which the ... of humans on declining animal numbers. This decline matters ... spiders, crustaceans, slugs and worms bring to our day-to-day ... for nutrient cycling, water filtration and human health. , ... by UCL, Stanford and UCSB, focused on the demise ...
(Date:7/24/2014)... cars ply silent freeways, solar panels blanket rooftops and ... from howling winds and from the blazing desert sun. ... technically and economically feasible to convert California,s all-purpose energy ... in Energy , the plan shows the way ... California that could create tens of thousands of jobs ...
Breaking Biology News(10 mins):UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 2UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 3Invertebrate numbers nearly halve as human population doubles 2Invertebrate numbers nearly halve as human population doubles 3Stanford study shows how to power California with wind, water and sun 2Stanford study shows how to power California with wind, water and sun 3Stanford study shows how to power California with wind, water and sun 4
... complex process. Candidate drugs are evaluated and assessed based ... rats or mice. Each class of drugs, from antidepressants ... labor-intensive process that leaves plenty of room for human ... procedures fail to effectively produce new medications. Now, ...
... What is myDNA Safe? myDNA Safe is an affordable ... individual,s entire genome. DNA Spectrum recently released this industry ... positioned to revolutionize the genetic testing industry. ... has not only taken an advance approach to storing ...
... deliciously edible, such as a fly, which he wraps up nicely in ... transfer sperm while she is eating the gift. If he remembers to ... than if he forgot, and the duration of the copulation is longer. ... a female spider, the sperm is stored in a special organ from ...
Cached Biology News:Finding psychiatric drugs in the movements of mice 2Finding psychiatric drugs in the movements of mice 3DNA SPECTRUM LAUNCHES GROUNDBREAKING DNA STORAGE PRODUCT 2
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (F1676) or contact customer s...
Mouse monoclonal [YPF19] to Yersinia pestis F1 antigen ( Abpromise for all tested applications)....
... CLS number is a new product ... product number. If showing no availability ... Sigma-Aldrich number (E6152) or contact customer ... H diam. 11.25 6.40 ...
... three Adept CE 4100 high pressure dual ... in one microlitre increaments. The ground ... added flexibility. The WaveQuest provides ... detection and provides superior stability . ...
Biology Products: